Register for free to listen to this article
Listen with Speechify
0:00
1:00
ST. LOUIS—Sigma-Aldrich Corp. announced in April that it hasacquired all outstanding shares of Cleveland, Ohio-based, Research OrganicsInc., to expand the company's buffer production capacity and to increase itsportfolio of PharmaGrade raw materials for the biopharmaceutical and diagnosticmarkets.
 
 
Founded in the 1950s, Research Organics was a pioneer inmanufacturing zwitterionic biological buffers and developing the HEPES bufferas an industry standard. Research Organics is now a supplier of high-puritybiochemicals for use in molecular biology, diagnostics, cell culture,pharmaceuticals, biopharmaceuticals, life sciences and biotechnology, and willtransition into SAFC, the custom manufacturing and services business unit ofSigma-Aldrich.
 
 
Financial terms of the purchase were not disclosed.Sigma-Aldrich said it expects the acquisition to be neutral to earnings pershare in 2012.
 
"This acquisition is an outstanding complement to ourexisting raw materials portfolio and will help us provide more innovativesolutions for some of our customers' toughest supply challenges," said GillesCottier, executive vice president of Sigma-Aldrich and president of SAFC, in astatement. "It will also enable us to provide SAFC's customers with true dualsourcing of buffers from two of the world's leading manufacturing sites."
 
"Joining Sigma-Aldrich is positive for Research Organics,our employees, customers and the city of Cleveland," added Rob Sternfeld,president of Research Organics. "The acquisition provides the resources toexpand the growth of our business, to enhance our product line and to upgradeour facilities to meet ever changing industry requirements. We will continue toprovide our customers with the superior quality and service they deserve andhave come to expect."
  


Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue